Changing Nature of High Risk Patients Undergoing Radical Prostatectomy

Journal of Urology

Volumn 177, Issue 1, 2007, Pages 113-117

  Kane, Christopher J ^a,b   Presti Jr , Joseph C ^c   Amling, Christopher L ^d   Aronson, William J ^e   Terris, Martha K ^f   Freedland, Stephen J ^g  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g DURHAM VA MEDICAL CENTER   (United States)

Author keywords

adenocarcinoma; outcome assessment (health care); prostate; prostate specific antigen; prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; DATA BASE; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TIME FACTORS;

EID: 33845388656     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.08.057     Document Type: Article

References (20)

1. Cooperberg M.R., Lubeck D.P., Mehta S.S., and Carroll P.R. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 170 (2003) S21
2. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969
3. Meng M.V., Elkin E.P., Latini D.M., Duchane J., and Carroll P.R. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 173 (2005) 1557
4. Sciarra A., Gentile V., Voria G., Mariotti G., Seccareccia F., Pastore A., et al. Role of radical retropubic prostatectomy in patients with locally advanced prostate cancer: the influence of Gleason score 8-10. Urol Int 70 (2003) 186
5. Skinner E.C., and Glode L.M. High-risk localized prostate cancer: primary surgery and adjuvant therapy. Urol Oncol 21 (2003) 219
6. Freedland S.J., Amling C.L., Dorey F., Kane C.J., Presti J.C., Terris M.K., et al. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology 60 (2002) 670
7. Clegg L.X., Li F.P., Hankey B.F., Chu K., and Edwards B.K. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 162 (2002) 1985
8. Ludgate C.M., Bishop D.C., Pai H., Eldridge B., Lim J., Berthelet E., et al. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation. Int J Radiat Oncol Biol Phys 62 (2005) 1309
9. Prepelica K.L., Okeke Z., Murphy A., and Katz A.E. Cryosurgical ablation of the prostate: high risk patient outcomes. Cancer 103 (2005) 1625
10. Sharkey J., Cantor A., Solc Z., Huff W., Chovnick S.D., Behar R.J., et al. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. Brachytherapy 4 (2005) 34
11. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095
12. Kattan M.W., Wheeler T.M., and Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17 (1999) 1499
13. Bolla M., van Poppel H., Collette L., van Cangh P., Vekemans K., Da Pozzo L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572
14. Steinberg G.D., Epstein J.I., Piantadosi S., and Walsh P.C. Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol 144 (1990) 1425
15. Stephenson A.J., Shariat S.F., Zelefsky M.J., Kattan M.W., Butler E.B., Teh B.S., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325
16. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433
17. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 23 (2005) 4975
18. Ghani K.R., Grigor K., Tulloch D.N., Bollina P.R., and McNeill S.A. Trends in reporting Gleason score 1991 to 2001: changes in the pathologist's practice. Eur Urol 47 (2005) 196
19. Thompson I.M., Canby-Hagino E., and Lucia M.S. Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst 97 (2005) 1236
20. Carducci M.A., and Carroll P.R. Multidisciplinary management of advanced prostate cancer: changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials. Urology 65 (2005) 18